Program proposal deadline October 8
Jeanan Yasiri Moe
Director of Strategic Communications
[email protected] | (608) 960-9892
MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer to clinical testing, a “bench to bedside” approach. The program invests in the development of drug-like molecules using industry-centric drug discovery resources and approaches led by a team of preclinical drug discovery experts.
We invite researchers to set up a meeting with Jon Young to discuss their program and learn more about WARF Therapeutics. Principal investigators are invited to submit project proposals by October 8, 2021, which will be reviewed at our fall Scientific Advisory Board (SAB) meeting.
Projects eligible for WARF Therapeutics
- UW-Madison or Morgridge Institute for Research principal investigators
- Translational research with a validated target and therapeutic disease hypothesis
- Patent not required
We meet with researchers throughout the year and the WARF Therapeutics SAB reviews proposals twice a year. Projects submitted by October 8 will have a review meeting in November. Another review will be held in spring 2022.
The current WARF Therapeutics portfolio includes six projects, the majority of which are in oncology. However, we are agnostic to disease indication and drug modality.
About WARF Therapeutics
Consistent with WARF’s mission to support UW-Madison research and make a global impact, WARF Therapeutics is a major initiative to move new pharmaceuticals closer to patients and the marketplace. WARF Therapeutics will select validated targets, invest in the discovery of therapeutic agents, lead them through preclinical development, and position them towards commercialization and to improve the lives of patients. More at warf.org/therapeutics.
The Wisconsin Alumni Research Foundation (WARF) helps steward the cycle of research, discovery, commercialization and investment for the University of Wisconsin–Madison. Founded in 1925 as an independent, nonprofit foundation, WARF manages more than 2,000 patents and an investment portfolio as it funds university research, obtains patents for campus discoveries and licenses inventions to industry. For more information, visit warf.org.